EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
10 Jul 2018

New EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems and makes recommendations for equitable access for patients in Europe

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personal...

Read more
02 Jul 2018

EBE announces its 2018-2020 Board of Directors

Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 J...

Read more
28 May 2018

EBE statement on the European Commission’s proposal to introduce an SPC manufacturing waiver, which puts patient care at risk

Brussels – After the European Commission released its proposal to introduce a Supplementary Protection Certificates (SPCs) manufacturing waiver today, the European Biopharmaceutical Enterprises (EBE...

Read more
02 Aug 2018

EBE View on the SPC Manufacturing Waiver

The European Biopharmaceutical Enterprises (EBE) has just released its latest position paper, raising concerns on how the SPC manufacturing waiver will affect innovative biopharmaceutical companies,...

Read more
23 Jul 2018

EBE-EFPIA Reflection Paper: An Industry Perspective on Article 117 of the EU Medical Devices Regulation and the Impact on how Medicines are Assessed

With the publication of the new Regulation on Medical Devices (MDR, Regulation (EU) 2017/745) comes an important amendment to the medicines legislation, in Article 117. As part of the marketing author...

Read more
15 Jan 2018

EBE reflection paper on “Medicinal product incorporating a drug delivery device component: An Industry Perspective on the EU marketing application technical requirements, regulatory review process and post-approval device related change assessment”

Within the European Biopharmaceutical Enterprises (EBE), a working group focused on EU specific topics relating to those integral combination products, which are regulated as medicinal products but wh...

Read more
20 Jun 2018

Incentives, IP and Smaller Companies: The Story of uniQure

Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands  and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe geneti...

Read more
07 Jun 2018

KPMG Report: Site Selection for Life Sciences Companies in Europe 2018

EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...

Read more
14 Mar 2018

European Investment Bank Report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”

EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of necessary...

Read more

From Twitter

Policy makers should stand ready to engage in a constructive dialogue on the #SPC manufacturing waiver, as it would disadvantage #biopharmaceutical companies, particularly #SMEs - see our position paper here: https://t.co/CXIDcKznZF

Our latest @EBE_EU - @EFPIA study shows that to advance #personalisedmedicine we need continued investment and cooperation in next generation testing infrastructure to ensure access to diagnostics https://t.co/ipNbCMo32N #biotech

We hope our new study will help provide the incentive to move #personalisedmedicine to the top of agenda in Europe, so that all EU citizens can benefit https://t.co/72hTiwm0Te #biotech

Follow us